Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)

被引：0
|
作者：
Thieblemont, Catherine
Wang, Kaijun
Keeping, Sam
Zhang, Ina
Yang, Keri
Tang, Boxiong
Mohseninejad, Leyla
机构：
[1] Hop St Louis, Paris, France
[2] BeiGene USA Inc, San Mateo, CA USA
[3] BeiGene Switzerland GmbH, Basel, Switzerland
[4] PRECISIONheor, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19527
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Ibrutinib for treatment of relapsed-refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison of 3 randomized phase 3 trials
    Burger, J. A.
    Munir, T.
    Ghia, P.
    Seymour, J. F.
    Rogers, K. A.
    Huang, H. -H.
    Moreno, C.
    Neumayr, L.
    Abbazio, C.
    Sharman, J. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 216 - 217
  • [22] Ibrutinib for Treatment of Relapsed-Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison of 3 Randomized Phase III Trials
    Burger, Jan
    Ghia, Paolo
    Munir, Talha
    Seymour, John F.
    Rogers, Kerry
    Huang, Hsin-Hui
    Moreno, Carol
    Neumayr, Lynne
    Abbazio, Christopher
    Sharman, Jeff P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S322 - S323
  • [23] Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+NSCLC
    Lu, S.
    Fan, Y.
    Yu, Y.
    Dong, X.
    Li, J.
    Zhao, J.
    Tao, S.
    Chen, M.
    Chen, Y.
    Liu, Y.
    Xu, J.
    Hu, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S679 - S679
  • [24] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
  • [25] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
    Vitolo, Umberto
    Merli, Michele
    Norasetthada, Lalita
    Wassenaar, Timothy Robert
    Martin, Eva Maria Donato
    Bobillo, Sabela
    Shen, Biyi
    Flink, Dina M.
    Zhu, Min
    Chandrasekharan, Soujanya
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Cordoba, Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Matching-Adjusted Indirect Comparison of Cabozantinib (C) Versus Regorafenib (R) in Advanced Hepatocellular Carcinoma (HCC)
    Venerito, Morino
    Kelley, R. K.
    Mollon, P.
    Blanc, J. F.
    Daniele, B.
    Yau, T.
    Cheng, A. L.
    Valcheva, V.
    Azocar, A. Remiro
    Baio, G.
    Li, Y.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 60 - 60
  • [27] Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma
    Telford, Claire
    Kabadi, Shaum M.
    Abhyankar, Sarang
    Song, Jinlin
    Signorovitch, James
    Zhao, Jing
    Yao, Zhiwen
    CLINICAL THERAPEUTICS, 2019, 41 (11) : 2357 - 2379
  • [28] Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.
    Budde, L. Elizabeth
    Coleman, Morton
    Stevens, Don A.
    Ma, Shuo
    Patti, Caterina
    Levy, M. Yair
    Lossos, Izidore S.
    Geethakumari, Praveen Ramakrishnan
    Lam, Selay
    Calvo, Roser
    Higgins, Kara
    Strati, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation
    Chen, Clara
    Armand, Philippe
    Rogula, Basia
    Johnston, Karissa
    Peterson, Derek
    Connors, Joseph M.
    Lozano-Ortega, Greta
    BLOOD, 2019, 134
  • [30] Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Hamadani, Mehdi
    Chen, Lei
    Song, Yan
    Xu, Michael K.
    Liao, Laura
    Caimi, Paolo F.
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E738 - E744
12345